Abivax appoints new HR Director
Ida Hatoum will be responsible for leading Abivax's growth strategy in the United States and Europe, to ensure that the Company has the right people in place to successfully complete its Phase 3 clinical program for obefazimod in ulcerative colitis", the company states.
In a second phase, Abivax will aim for market access and commercialization of its drug candidate, subject to obtaining the necessary regulatory approvals.
With over 15 years' experience, Ida Hatoum will be based at Abivax's East Coast subsidiary.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction